Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA (pegloticase injection) at AGC's Copenhagen Facility
(1) Seattle, April 30, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA (pegloticase injection) - a biologic medicine for treatment of chronic gout refractory to conventional therapies (uncontrolled gout), at its state-of-the-art facility in Copenhagen, Denmark. "We are extremely happy to further expand our strategic partnership with Horizon by leveraging the microbial capacity...